TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Thyroid Cancer

166 clinical trials

94 active
/
166 total (since 2015)
28
Phase 1 Active
59 total
58
Phase 2 Active
104 total
18
Phase 3 Active
25 total
4
Phase 4 Active
9 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Eli Lilly 3 0 0
Exelixis 3 0 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2 2 0
Pfizer 2 0 0
Roche 1 1 2
Novartis 1 1 0
Solve Therapeutics 1 0 0
Alpha Fusion Inc. 1 0 0
AccSalus Biosciences, Inc. 1 0 0
Chongqing Precision Biotech Co., Ltd 1 0 0
Merck 1 0 0
Beijing Scitech-Mq Pharmaceuticals Limited 1 0 0
Sensei Biotherapeutics, Inc. 1 0 0
Apollomics Inc. 1 0 0
ModeX Therapeutics, An OPKO Health Company 1 0 0
NCT07444723 NOT YET RECRUITING
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=193
NCT06554652 RECRUITING
Selective Neck Dissection Versus Modified Neck Dissection in PTC
Fudan University n=250
NCT06558981 RECRUITING
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
Fudan University n=124
NCT07440290 NOT YET RECRUITING
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Cancer Research UK n=30
NCT07383246 RECRUITING
CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=150
NCT06860971 RECRUITING
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=144
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT04940052 ACTIVE NOT RECRUITING
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis Pharmaceuticals n=153
NCT05768178 RECRUITING
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK n=30
NCT07239674 NOT YET RECRUITING
Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC
West China Hospital n=646
NCT05999630 RECRUITING
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
Vanderbilt University Medical Center n=100
NCT04290663 RECRUITING
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
Centre Francois Baclesse n=476
NCT03690388 ACTIVE NOT RECRUITING
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis n=187
NCT04211337 ACTIVE NOT RECRUITING
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Loxo Oncology, Inc. n=291
NCT06791005 RECRUITING
A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.
Second Affiliated Hospital of Xi'an Jiaotong University n=400
NCT03570021 RECRUITING
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=1,000
NCT06082180 RECRUITING
A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=1,199
NCT05468554 NOT YET RECRUITING
Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
Medical University of Bialystok n=160
NCT04971473 COMPLETED
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=201
NCT04760288 WITHDRAWN
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Hoffmann-La Roche
NCT02966093 COMPLETED
A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
Eisai Co., Ltd. n=151
NCT03602495 TERMINATED
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=204
NCT03280264 COMPLETED
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
Kyowa Kirin Co., Ltd. n=18
NCT02586350 COMPLETED
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=91
NCT01701349 WITHDRAWN
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
Mateon Therapeutics

Data: ClinicalTrials.gov